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Recent years have shown a rapidly growing interest among
clinical chemists, clinical cardiologists and emergency phy-
sicians in the use of new biochemical markers for risk
stratification of patients with acute coronary syndrome
(ACS). It was demonstrated across a wide range of ACS
patient populations (including low-, intermediate-, and
high-risk) that evidence of myocardial injury upon presen-
tation is a strong, independent prognostic indicator for
short- and long-term adverse outcomes (1–6). The cardiac
troponins T (cTnT) and I (cTnI) are especially useful in
detecting (small amounts of) myocardial damage because of
their cardiac specificity and the availability of new, rapid,
and highly sensitive assays. Cardiac troponin becomes
elevated in plasma early after the onset of symptoms (7).
See page 1818
The cardiac troponins are virtually absent in plasma of
healthy subjects; therefore, even small elevations are indic-
ative of myocardial necrosis. In addition, false positive
troponin results are rare: an abnormal cardiac troponin may
be present only in patients with a readily recognizable
clinical entity such as muscular dystrophy, and false positive
results in patients with renal failure are less frequent with
new-generation assays in the case of cTnT (8). As a
consequence, the National Academy of Clinical Biochem-
ists and “the joint ESC-ACC working group for the
redefinition of myocardial infarction” have recommended
that an elevated troponin become part of the definition of
acute myocardial infarction (AMI) (8,9). Redefining AMI
to include patients with very small amounts of myocardial
injury as detected with the new immunoassays may have
important socioeconomic (and legal and financial) conse-
quences (10). It will also have consequences with respect to
the AMI definition in large epidemiological studies. How-
ever, the definition for the clinical diagnosis of AMI should
not be dependent on local reimbursement practices or
national psychology, and problems with the epidemiological
definition can be overcome. There is no clear (patho)phys-
iological or clinical distinction between “minor myocardial
damage,” “microinfarct” and “infarctlet” characterized by a
biochemical marker peak value below or equal to a prede-
termined cut-off value versus “true AMI” with a peak value
just above the cut-off level. There is on the other hand a
clear difference in risk between patients with, and patients
without, evidence of myocardial injury. Moreover, an incre-
mental risk exists: the higher the troponin concentrations,
the higher the prospective risk (3,5), indicating that using
the dichotomy between the classic AMI and non-AMI is
clinically not meaningful. Finally, with troponin as the gold
standard, with its superior sensitivity and specificity, an
abnormal troponin in the setting of an ACS will eventually
become equivalent to “myocardial damage” or AMI accord-
ing to the revised definition. Patients presenting with typical
chest pain can thus be classified upon admission as presenting
with an ACS either with ST elevation or with no ST
elevation on the electrocardiogram and, subsequently, be
risk-stratified in the following hours as either with or without
evidence of myocardial injury (as assessed by a combination
of serial CK-MBmass and cardiac troponin measurements)
(8).
The early establishment of evidence of myocardial dam-
age in patients presenting with non–ST elevation ACS is
important: such patients more often have significant coro-
nary artery disease (CAD), and they more often have
complex lesions and visible thrombus formation on their
coronary angiogram (11). In patients with unstable angina,
cTnT identified patients with increased procoagulant activ-
ity and was closely related to plasma levels of molecular
markers of hemostatic activation (12).
Can we now decide on the optimal treatment for patients
with non–ST elevation ACS and an abnormal troponin, as
opposed to patients with a normal troponin?
It was shown in post-hoc subgroup analyses from the
PRISM study (which evaluated the treatment with of
tirofiban for non–ST elevation ACS patients), the CAP-
TURE study (which evaluated the effect of abciximab in
patients with refractory unstable angina, scheduled to un-
dergo a percutaneous intervention) and the FRISC-I study
(which evaluated the use of low-molecular-weight heparin
in unstable angina patients) that non–ST elevation ACS
patients with an abnormal troponin are likely to benefit
from treatment with glycoprotein IIb/IIIa inhibitors and/or
treatment with low-molecular-weight heparin, whereas in
patients with a normal troponin, no treatment effect was
seen (13–16). Indirectly, this apparent effect of treatment
directed against platelet aggregation and trombin formation
in patients with an abnormal troponin corroborates the
hypothesis of embolization of micro-trombi as the explana-
tion of troponin release in non–ST elevation ACS patients
(17).
These analyses have to be put in a new perspective
however, in light of the results of the GUSTO-IV ACS
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study that was recently presented at the European Society of
Cardiology meeting in Amsterdam. GUSTO IV ACS
tested medical treatment with abciximab, in addition to
aspirin and heparin, and risk stratification with troponins
was tested prospectively. To the surprise of many, although
60% of the patients had an abnormal troponin, 30-day
incidence of death/MI was only 8.0% in the placebo group.
Moreover, treatment with abciximab provided no benefit.
These results indicated that, at present, routine treatment
with a glycoprotein IIb/IIIa inhibitor in non–ST elevation
ACS patients cannot be recommended solely on the basis of
an abnormal troponin. Whether routine early revasculariza-
tion is beneficial to these patients, as was shown in one
randomized clinical trial, the FRISC-II trial, is a matter of
ongoing debate (18). Early angiography and subsequent
revascularization for high-risk non–ST elevation ACS pa-
tients, such as patients with an abnormal troponin, are now
included in the recommendations of the European Society
of Cardiology Task Force report (19).
The next question to be answered is: “What is the
optimal strategy for patients presenting with suspected
non–ST elevation ACS, but without evidence of myocardial
injury? It has become increasingly clear that, depending on
patient selection and a priori likelihood of disease, major
cardiac events do occur in troponin-negative patients. It was
demonstrated by Hamm et al. (20), in low-risk patients
triaged in the emergency room, that a normal troponin T or
I can identify patients that have a very low incidence of
adverse cardiac events in the following months. The authors
suggested that these patients may be safely discharged.
However, the majority of intermediate-risk patients pre-
senting with chest pain that subsequently have major
complications during short-term follow-up do not have an
elevated troponin. Although physicians are under pressure
because of financial constraints to avoid unnecessary admis-
sions and reduce hospital length of stay, they should be
aware of this apparent inability of a normal cardiac troponin
to exclude a large proportion of patients who either have
significant disease or will develop complications, depending
on the patient population studied. The study by Kontos et
al. (21) in this issue of the Journal is welcome in that respect,
as it emphasizes that a normal cardiac troponin I does not by
itself exclude trouble. The study comprised a large cohort of
1,929 consecutive patients admitted to the hospital from the
emergency department for possible AMI. The investigators
performed serial sampling as part of an 8 h rapid diagnostic
protocol, using a previously published cardiac troponin I
assay. The cut-off value chosen for an abnormal troponin I
in this study was 1.0 ng/ml (to maximize sensitivity) on the
basis of ROC analysis, instead of using the information
provided by the manufacturer. The study confirms that
sensitivity of a positive troponin I for AMI (evolving AMI
on admission) is high (96%). Patients without AMI but
with an abnormal troponin I were more likely to have
complications (43% vs. 12%) or significant disease (41% vs.
17%). An important finding however, was that sensitivity
for complications or significant disease was low (14% and
21%, respectively), which remained unchanged when pa-
tients with ischaemic electrocardiograms were excluded
from the analysis. The study by Kontos et al. (21) is
consistent with, and extends, prior studies that reported the
negative predictive value of cardiac troponins for the occur-
rence of major complications in patients with moderate risk.
In a previous report from a relatively small study, no deaths
(0%) and four AMIs (5.8%) occurred at 30 days in the 69
patients with normal cTnI, compared with two deaths
(9.1%) and four AMIs (18.2%) in the 22 patients with
elevated cTnI (22). In a more recent study that included
1,047 patients, Polanczyk et al. (4) reported that among
patients that did not meet the criteria for AMI, cTnI was
elevated in only 26% who had major cardiac complications
within the first 72 h. The definition of “major complica-
tions” was identical to that used in the study by Kontos et al.
(21) and the cTnI assay used was from the same manufac-
turer. In another study by Johnson et al. (23) among patients
who did not meet criteria for AMI, cardiac troponin T was
elevated within the first 24 h in 31% of patients who had
major complications. The study by Kontos et al. (21) is
welcome in another respect: until adequate cTnI standard-
ization is available, thresholds established for individual
assays from specific manufacturers should not be general-
ized, and the clinical efficacy of each cTnI assay at a given
decision limit should be established in a carefully conducted
study (24).
An important limitation of the study by Kontos et al. (21)
was that cTnI results were available to the attending
clinicians, as were the results of nuclear myocardial perfu-
sion imaging, all of which may have affected subsequent
care. The composite outcome measure used by Kontos et al.
(21) is somewhat confusing: significant CAD may of course
be present without plaque instability or intracoronary
thrombus, and a normal cTnI in the majority of these
patients is not surprising. Clinical sequelae related to ar-
rhythmias or congestive heart failure were included in the
definition of “significant complications,” which may be
unrelated to the presence of an ACS. Furthermore, al-
though Kontos et al. (21) demonstrated in a multivariate
analysis that a positive troponin was the most important
predictor of AMI, death or significant coronary disease,
readily available clinical variables upon admission that are
important prognostic indicators, such as heart rate, systolic
blood pressure or signs of heart failure (25), were not
included in the analysis.
Further prospective studies are needed to test strategies
for early risk stratification and tailored treatment in non–ST
elevation ACS patients—a statement that seems even more
true, now that the results of the GUSTO-IV ACS study are
available. Low-, intermediate- and high-risk patient popu-
lations can be identified, using simple risk stratification that
includes clinical and electrocardiographic variables obtained
upon admission and an observation period of 6 h to 12 h
during which the presence and extent of myocardial damage
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can be assessed. Low-risk patients who do not have evidence
of myocardial damage and who show an uneventful obser-
vation period can be safely discharged and managed at the
outpatient clinic. By contrast, intermediate- and high-risk
patients should be admitted even in the absence of evidence
of myocardial injury. Future studies may also confirm recent
evidence that an elevated C-reactive protein concentration
in the blood of patients presenting with a non–ST elevation
ACS may have important prognostic information, in addi-
tion to the prognostic information contained in the patients
troponin levels.
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